SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia—a phase II randomised control trial study protocol

SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia—a phase II randomised control trial study protocol

Abstract Background Sodium valproate (VPA) has been associated with a reduced risk of head and neck cancer development. The potential protective mechanism of action is believed to be via inhibition of histone deacetylase and subsequent epigenetic reprogramming. SAVER is a phase IIb open-label, rando...

Full description

Bibliographic Details
Main Authors: Caroline McCarthy, Joseph Sacco, Stefano Fedele, Michael Ho, Stephen Porter, Triantafillos Liloglou, Bill Greenhalf, Max Robinson, Bridget Young, Silvia Cicconi, Seema Chauhan, Binyam Tesfaye, Richard Jackson, Frances Sherratt, Richard Shaw
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Trials
Subjects:
Oral epithelial dysplasia
Sodium valproate
Epigenetic reprogramming
Drug repurposing
Randomised controlled trial
Chemoprevention
Online Access:https://doi.org/10.1186/s13063-021-05373-8

Similar Items

Similar Items